|
||||
|
Welcome to your new online resource for The Lancet, The Lancet Infectious Diseases, The Lancet Oncology, and The Lancet Neurology. In addition to the Lancet journals' medical news, research, review, and opinion, the new site offers more functionality and features and will continue to expand in the coming months. We thank the many Lancet readers and authors worldwide who have helped shape the new website, and invite you to tell us what you think. Listen to Richard Horton and Harriet Bell introducing the new website in our launch podcast. (mp3, 10:27 mins, 9.57Mb) |
|
||
|
The WHO Commission on Social Determinants of Health recommends three areas to close the gap in health inequality: improvements in daily living; schemes to tackle the inequitable distribution of power, money, and resources; and measurement of health inequalities within countries and globally. The Lancet publishes a themed issue on the social determinants of health, including a summary of the key findings and recommendations from the WHO Commission |
More US primary care doctors needed
Comment The Lancet (online Nov 3)
|
Clostridium difficile
Review The Lancet Infectious Diseases (online Nov 1)
|
Post-herpetic neuralgia patch
|
As Barack Obama swept to victory on Nov 4, there are already early hopes that legislation to increase health coverage for children will be a priority for the new government.
The US Department of Veterans Affairs has reported that almost 15% of soldiers returning from Iraq and Afghanistan who have sought medical care through the VA system say they experienced some form of "military sexual trauma". Forms of trauma ranged from unwelcome advances to rape.
The Global Fund to fight AIDS, Tuberculosis and Malaria has halted the release of US$12 million allocated to Uganda in 2003-04, because of poor management of funds. With an estimated 1 million Ugandans living with HIV/AIDS, the country will need to maintain donations from the Global Fund and other donors for its ambitious plan for HIV/AIDS treatment and prevention, predicted to cost $2 billion over 5 years.
A prosthetic heart, that is shaped like the human organ and pumps blood in the same rhythm, could be ready to implant into patients by 2011. The heart was developed by cardiac expert Alain Carpentier and engineers from the aerospace group EADS. It uses electronic sensors to control heart rate and blood flow, and includes chemically enhanced animal tissue to reduce the risk of rejection by the patient’s immune system.
More This Week in Medicine:
1. | Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications
in patients with type 2 diabetes (UKPDS 33) Research (1998) Lancet 352 (9131), pp. 837-853
|
2. | MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: A randomised placebo-controlled
trial Research (2002) Lancet 360 (9326), pp. 7-22
|
3. | Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the
Hypertension Optimal Treatment (HOT) randomised trial Research (1998) Lancet 351 (9118), pp. 1755-1762
|
4. | A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) Research (1996) Lancet 348 (9038), pp. 1329-1339
|
5. | Peginterferon alfa-2b plus ribavirin compared with interferonalfa-2b plus ribavirin for initial treatment of chronic hepatitis
C: A randomised trial Research (2001) Lancet 358 (9286), pp. 958-965
|
1. | Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind,
placebo-controlled trial Research (2008) Lancet 372 (9645), pp. 1223-1230
|
2. | Thrombolysis with alteplase 3-4·5 h after acute ischaemic stroke (SITS-ISTR): an observational study Research (2008) Lancet 372 (9646), pp. 1303-1309
|
3. | China and global health Comment (2008) Lancet 372 (9648), pp. 1439-1441
|
4. | Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled
trial Research (2008) Lancet 372 (9647), pp. 1385-1393
|
5. | Childhood outcomes after prescription of antibiotics to pregnant women with preterm rupture of the membranes: 7-year follow-up
of the ORACLE I trial Research (2008) Lancet 372 (9646), pp. 1310-1318
|